Home
    Disclaimer

    9-Me-BC Stats & Data

    9-methyl-norharman
    Chemical Class Tryptamine
    Psychoactive Class Psychedelic
    Half-Life Unknown in humans; rodent i.p. data suggest ~2–4 h, with longer functional effects due to tissue accumulation.

    Effect Profile

    Curated
    Psychedelic 3.6

    Moderate visuals with mild body load, low headspace

    Visual Intensity×3
    6
    Headspace Depth×3
    2
    Auditory Effects×1
    0
    Body Load / Somatic Effects×1
    5

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; rodent i.p. data suggest ~2–4 h, with longer functional effects due to tissue accumulation.
    Addiction Potential
    Low – lacks classic euphoria; some users redose chasing motivation. Prefer finite cycles (e.g., ≤14 days) with equal-length washouts to limit tolerance and sleep disturbance.

    Tolerance Decay

    Full tolerance 10d Half tolerance 4d Baseline ~10d

    Tolerance pattern is inferred from community cycles and MAOI-class experience; no formal human data. Anecdotally, consecutive heavy dosing for a week can blunt effects; spacing doses and cycling (≤14 days on, ≥14 off) is commonly used to mitigate this.

    Cross-Tolerances

    dopaminergic stimulants
    30% ●○○
    other reversible MAOIs (class effect)
    20% ●○○

    Harm Reduction

    drugs.wiki

    • 9‑Me‑BC inhibits MAO-A (IC50 ≈1 µM) and MAO‑B (IC50 ≈15.5 µM) in vitro and upregulates neurotrophic factor genes (e.g., BDNF) in astrocytes; these properties likely underlie reported pro-motivational effects but also create MAOI‑type interaction risks. • Compared with irreversible MAOIs, reversible/weak MAO‑A inhibition confers a lower tyramine hazard, but large tyramine loads still reduce the safety margin; avoid oversized aged/fermented meals and be extra cautious if any other MAOI is on board. • MAOI coadministration with serotonergic drugs (e.g., SSRIs/SNRIs, MDMA, tramadol, dextromethorphan) can precipitate serotonin toxicity; do not combine and respect adequate washouts. • Combining with sympathomimetics (amphetamines, ephedrine/pseudoephedrine, phenylephrine) increases hypertensive crisis/arrhythmia risk; avoid. • In Parkinson’s regimens, adding MAO inhibitors to levodopa increases the chance of dyskinesias and insomnia; similar dopaminergic potentiation could occur if 9‑Me‑BC meaningfully inhibits MAO in vivo. • β‑Carbolines can act as photosensitizers that damage DNA under UVA; users frequently report photosensitivity/photophobia—minimize UV exposure, wear sunglasses/UPF clothing, and avoid tanning beds during cycles. • Oral and sublingual use are most common; sublingual solutions often sting and can numb taste—if irritation occurs, shorten contact time or switch to oral dosing. Intranasal use has frequent reports of painful irritation and is not advised. • Because some β‑carbolines can oxidize to permanently charged β‑carbolinium species with dopaminergic toxicity in experimental models, store 9‑Me‑BC away from light/heat, in airtight amber containers; avoid strong oxidizers. This is a theoretical quality-control precaution, not a documented 9‑Me‑BC clinical risk. • Expect insomnia and anxiety if taken late or at higher doses; dose in the morning, avoid caffeine late in the day, and consider non-sedating sleep hygiene first. Sexual side‑effects are reported anecdotally and are plausible by MAOI class effects. • Source quality varies; prefer suppliers providing third‑party analytics. Weigh accurately (milligram scale) or use volumetric solutions to avoid accidental high dosing and dust inhalation.

    ← Back to 9-Me-BC